Mycoplasma Testing Market Share, Business Size, Growth Factors and Forecast 2025 – 2032
Growth and innovations in the diagnostic sector have created an opportunity for mycoplasma testing market size because of the rising contaminations of mycoplasma within the pharmaceutical and biotechnology industry producing mycoplasma testing products. Main mycoplasma testing market growth drivers include rising research initiatives in the biotechnology and the biopharmaceutical industries, and the higher demand of the mycoplasma testing kits by the biopharmaceutical industry.
Mycoplasma Testing Market size was valued at USD 790.2 Million in 2023 and is poised to grow from USD 867.72 Million in 2024 to USD 1834.48 Million by 2032, growing at a CAGR of 9.81% during the forecast period (2025-2032)
Get Your Free Sample Report Here @ https://www.skyquestt.com/samplerequest/mycoplasma-testing-market
The mycoplasma testing market share will increase due to emerging markets because of the better infrastructure for healthcare, an increased unmet healthcare demands, and the rising incidence of mycoplasma contamination. As a matter of fact, rules and regulations mandating testing for biologics and vaccines for mycoplasma contamination have been published by regulatory bodies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Due to this, a heightened demand for mycoplasma testing has been witnessed in the biopharmaceutical sector. Also, technical innovations are inclined to lead to the mycoplasma testing market share, including faster and more accurate procedures and equipment for mycoplasma testing. The latest instance is Minerva Biolabs GmbH's VenorGeM Advance assay, highly sensitive and specific, which targets mycoplasma contamination in biological matrices of cell cultures.
Mycoplasma Testing Market Segments Analysis:
Mycoplasma Testing Market is segmented by Product & Service, Technique, Application, End User, and Region.
Based on Product & Service, the market is segmented into Assays, Kits, & Reagents (NAT Assays, Kits, & Reagents; Enzyme-Linked Immunosorbent Assays, Kits, & Reagents, Elimination Kits, Stains, Other Assays, Kits, & Reagents), Instruments, Services.
Based on Technique, the market is segmented into Nucleic Acid Testing, Enzyme-Linked Immunosorbent Assay, Staining, Other Techniques. Based on Application, the market is segmented into Cell Line Testing, Virus Testing, End-Of-Production Cell Testing.
Based on End User, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic & Research Institutes, Cell Banks & Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Mycoplasma Testing Market Key Players:
Merck KGaA
Roche Diagnostics (A Division of F. Hoffmann-La Roche Ltd.)
Charles River Laboratories International, Inc.
Lonza Group Ltd.
Thermo Fisher Scientific, Inc.
Eurofins Scientific Group
Sartorius Stedim Biotech S.A.
Agilent Technologies, Inc.
Meridian Bioscience, Inc.
American Type Culture Collection
Bionique Testing Laboratories, Inc.
InvivoGen
PromoCell GmbH
Biological Industries Israel Beit Haemek Ltd.
Clongen Laboratories, LLC
Creative Bioarray
Nelson Laboratories Fairfield, Inc. (A Part of Sotera Health)
Norgen Biotek Corporation
Biotools B & M Labs, S.A.
GenBio (A Part of ExonHit Therapeutics SA)
GeneCopoeia, Inc.
Minerva Biolabs GmbH
Mycoplasma Experience
Savyon Diagnostics
ScienceCell Research Laboratories
Mycoplasma Testing Market Regional Insights:
According to the global mycoplasma testing market forecast, North America led the market in 2023 with a revenue share of 39.04%. A combination of several factors leads to a high mycoplasma testing market share.
Prevalence of respiratory disorders is also at a high level and the rising investment in biotechnology by major companies since its wide application in cancer research and developing novel biologics, vaccines, and drugs. Besides, through the development and integration of strict regulatory requirements, companies such as the FDA and the U.S. Department of Health and Human Services, in collaboration with the Centers for Disease Control and Prevention and the National Institutes of Health, continually advance standards on the testing of biological and microbiological safety of biomedical laboratories.
What's more, it likewise covers the request and give of the promoting research concentrate in the assessed figure time frame. Explained investigation of the market players with their profile, deals examination and serious scene is given in the report. Besides, organization, joint effort and consolidations in the business are referenced for the accommodation of the investigation of the global Mycoplasma Testing industry.
Related Reports:
https://www.dreamnews.jp/press/0000317459/ https://www.skyquestt.com/report/aquaculture-market
Looking ahead, the Mycoplasma Testing Market is poised for continued growth, driven by evolving consumer preferences and ongoing innovations. The trend towards sustainability is expected to strengthen, with more consumers seeking products that align with their values. Additionally, the integration of advanced technologies and digital platforms will likely further enhance market accessibility and consumer engagement. The global Mycoplasma Testing Market is a dynamic and evolving landscape, shaped by a confluence of trends and factors.
Browse Complete Report Mycoplasma Testing Market for Better Understanding - https://www.skyquestt.com/report/mycoplasma-testing-market
Contact Us:
SkyQuest Technology
1. Apache Way, Westford, Massachusetts 01886
USA (+1) 351–333–4748
Email: sales@skyquestt.com
Visit Our Website: https://www.skyquestt.com/
About Us:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology. We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific."
